Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWJNJ-10191584 is a histamine H4 receptor antagonist (Ki = 79.42 nM).1 It is selective for the histamine H4 receptor over the histamine H3 receptor (Ki = 3,981 nM). JNJ-10191584 inhibits eosinophil and mast cell chemotaxis (IC50s = 530 and 138 nM, respectively).2 It decreases colonic injury in a rat model of TNBS-induced colitis when administered at doses of 30 and 100 mg/kg and reduces colonic mucosal and submucosal thickness at 100 mg/kg in the same model.3 JNJ-10191584 (6 mg/kg) reduces the percentage of Th1, Th9, Th17, and regulatory T cells in the spleen, the expression of a variety of cytokines, including Ifng, Il9, and Tgfb1, in the brain, and the development of experimental autoimmune encephalomyelitis (EAE) in mice.4
WARNING This product is not for human or veterinary use.
1. Synthesis and structure-
2. Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: Potent human histamine H4 antagonists. J. Med. Chem. 48(26), 8289-8298 (2005).
3. Inhibitory effects of histamine H4 receptor antagonists on experimental colitis in the rat. Eur. J. Pharmacol. 522(1-3), 130-138 (2005).
4. Histamine H4 receptor antagonist ameliorates the progression of experimental autoimmune encephalomyelitis via regulation of T-